Infectious disease Archives

tuberculosis suicide cnrs embl Francis Crick antibiotic resistance immune

News and Trends 18 Feb 2019

Tuberculosis Treatment Kills Bacteria with Their Own Suicide Toxin

A European academic research collaboration has found a new potential weapon against antibiotic-resistant tuberculosis: its own toxins. Many types of bacteria, such as the pathogen responsible for the deadly lung disease tuberculosis, Mycobacterium tuberculosis, use toxins to stay alive. For example, these toxins can be useful when the bacteria are starved or infected by viruses, […]

February 18, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 1 Nov 2018

Llama Antibodies Could Be the Key to Universal Flu Prevention

Researchers have developed a new approach to prevent the flu that can protect against all seasonal strains of the virus. It also has potential to be effective for those that cannot get vaccinated. In a paper published in Science today, researchers at Janssen and The Scripps Research Institute have revealed a new approach to prevent […]

November 1, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

In Depth 1 Oct 2018

Could These Innovative Flu Vaccines Prevent Deaths From Deadly Outbreaks?

Despite more than a century of scientific endeavour, influenza remains one of the most deadly infectious diseases worldwide. Across Europe, many biotechs are working on novel solutions that could dramatically improve the protection rates offered by current vaccines. Some may even lead to the holy grail of influenza research – a universal flu vaccine. Each […]

October 1, 2018 - 8 minutesmins - By David Cox

News and Trends 7 Aug 2018

Update: Seaweed-Derived Treatment for Common Cold Approved in the EU

Update (07/08/2018): Marinomed Biotech has obtained EU approval to sell a nasal spray containing a polymer derived from red seaweed that can trap most common cold viruses to stop them from infecting us. Published on 19/07/2018 Marinomed Biotech’s antiviral treatment, which is derived from seaweed, could be used to treat the cause of respiratory […]

August 7, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 1 Aug 2018

London Biotech Raises €47M to Develop First Treatment Against RSV Virus

ReViral will dedicate the funds to run two clinical trials to test whether its antiviral can help patients at high risk from RSV infections. The respiratory syncytial virus (RSV) only causes mild cold symptoms in most people. But for small children and immunosuppressed patients, it can be deadly. “There are at present no approved therapies […]

August 1, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 8 Jun 2018

People with Innate Resistance to HIV Could Provide a Functional HIV Cure

In the process of studying HIV-infected patients who naturally don’t need therapy to control the virus, scientists have found what could become a functional cure for HIV infections. A team of researchers from France, Italy, the UK and Australia has identified a molecule that could be transferred to HIV-positive people to help […]

June 8, 2018 - 4 minutesmins - By Clara Rodríguez Fernández

Nabriva Therapeutics Pneumonia Antibiotic

News and Trends 23 May 2018

Another Pneumonia Antibiotic is Close to Treating Patients

Nabriva Therapeutics has obtained positive Phase III results for its antibiotic lefamulin and plans to seek FDA approval for the drug by the end of this year. Nabriva Therapeutics has obtained a second round of positive Phase III results for lefamulin, its antibiotic targeting community-acquired pneumonia. The drug was shown to be as effective as […]

May 23, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 22 May 2018

Celgene Partners With German Biotech to Develop Oncology Treatments

Evotec has entered into a collaboration with Celgene to identify new therapeutics in oncology with a focus on solid tumors. Evotec, based in Hamburg, has received an upfront payment of $65M (€55M) from US-based Celgene, one of the largest biotechs worldwide. The funding will be used to identify potential new cancer treatments with a focus on […]

May 22, 2018 - 2 minutesmins - By Alexander Burik

evotec sanofi infectious disease pipeline

More News! 8 Mar 2018

Evotec Takes Over Sanofi’s Infectious Disease Pipeline

Evotec will be getting over 10 assets, €60M upfront and about 100 scientists from Sanofi’s infectious disease research unit to work on developing new antimicrobials. Evotec has entered exclusive negotiations with Sanofi to accelerate infectious disease R&D through a new innovation platform located near Lyon, France, that will be open to academia, private companies, foundations and government agencies. Sanofi, […]

March 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 26 Feb 2018

This Oral Vaccine for Typhoid Raises €8M from International Investors

Prokarium has raised $10M (€8M) from Saudi, Swedish and Korean investors to support the clinical development of its oral vaccines for infectious diseases like typhoid. Since its foundation in 2012, Prokarium has been working on oral vaccines and it has developed a delivery platform that can be applied to any antigen used for vaccination. The biotech has […]

February 26, 2018 - 3 minutesmins - By Alex Dale

News and Trends 23 Feb 2018

Crack Open the Champagne, AiCuris’ Antiviral Launched in Germany

Update (23/02/2018): Merck Sharp & Dohme (MSD), licensee of AiCuris, has launched letermovir in Germany under the trade name Prevymis. The antiviral drug will be available to patients undergoing a hematopoietic stem cell transplant (HSCT) to prevent reactivation of latent human cytomegalovirus (CMV), which can prove lethal in the weakened state of this patients. Update (31/01/2018): […]

February 23, 2018 - 3 minutesmins - By Alex Dale

News and Trends 19 Feb 2018

Organ-on-a-Chip Technology Used to Spot New Hepatitis B Drug Targets

Scientists in London are the first in the world to test how pathogens like the hepatitis B virus interact with artificial human organs. Researchers at Imperial College London have used artificial human organs, or organs-on-chips, to replicate the make-up and physiology of the cells in whole organs. The study, published in Nature Communications, shows how the […]

February 19, 2018 - 3 minutesmins - By Alex Dale

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us